Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
Aurobindo Pharma Q4 PAT may dip 26.6% YoY to Rs 588.1 cr: Prabhudas Lilladher
Aurobindo Pharma Q3 PAT may dip 73% YoY to Rs 795.3 cr: Prabhudas Lilladher
Aurobindo Pharma Q2 PAT may dip 17.3% YoY to Rs 666.3 cr: Prabhudas Lilladher
Aurobindo Pharma Q1 PAT seen up 1.3% YoY to Rs 791.1 cr: KRChoksey
Aurobindo Q1 PAT may dip 1.7% YoY to Rs 767.6 cr: ICICI Direct
Aurobindo Q4 PAT seen up 6% YoY to Rs. 901 cr: Sharekhan
Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher
Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies
Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay
Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak
Aurobindo Pharma Q4 PAT seen up 18.2% YoY to Rs. 624.9 cr: Prabhudas Lilladher
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
Aurobindo Pharma Q3 preview: Profit may get a boost; outlook on US business key
Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan
Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct
Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila
Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance
Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities
Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan
Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher

Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher

Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct

Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher

Aurobindo Pharma Q4 PAT may dip 26.6% YoY to Rs 588.1 cr: Prabhudas Lilladher

Aurobindo Pharma Q3 PAT may dip 73% YoY to Rs 795.3 cr: Prabhudas Lilladher

Aurobindo Pharma Q2 PAT may dip 17.3% YoY to Rs 666.3 cr: Prabhudas Lilladher

Aurobindo Pharma Q1 PAT seen up 1.3% YoY to Rs 791.1 cr: KRChoksey

Aurobindo Q1 PAT may dip 1.7% YoY to Rs 767.6 cr: ICICI Direct

Aurobindo Q4 PAT seen up 6% YoY to Rs. 901 cr: Sharekhan

Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies

Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay

Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak

Aurobindo Pharma Q4 PAT seen up 18.2% YoY to Rs. 624.9 cr: Prabhudas Lilladher

Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings

Aurobindo Pharma Q3 preview: Profit may get a boost; outlook on US business key

Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan

Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance

Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities

Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan

Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct

Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz